Contact Us : 7030 300 400
Select city
Contact Us : 7030 300 400
Cart Cart 0
x

Recent Searches

x

Popular Cities

Book a Test Centre/
Laboratories Locator
Download Report
Centre Visit Home Collection
About Lupin Limited



 

About
Lupin

The Promise of Caring

Science can be a potent catalyst for change and transformation. This conviction in the power of science to improve health outcomes and uplift communities served as the guiding light for our founder, Dr. Desh Bandhu Gupta, and for Lupin, the company he founded in 1968.

DBG, as Mr. Gupta was fondly called, began teaching at the Birla Institute of Technology and Science in Pilani, Rajasthan, after completing his post-graduate degree in science. However, DBG had the desire to harness the power of science for his country – to bring about change and to improve healthcare in India.

Lupin commenced operations as a manufacturer of vitamins, and soon started producing drugs to combat tuberculosis (TB). The decision was anchored by DBG’s desire to reduce the burden of one of the most pervasive and debilitating diseases in India, despite stringent price controls on anti-TB drugs by the government.

Over the years, Lupin has grown and expanded into new areas and regions, manufacturing drugs that extend the promise of good health to communities across the globe. Beginning with two employees — a peon-cum-packer and a part-time typist — Lupin’s current global footprint spans 11 countries, across six continents. This journey has been made possible thanks to the vision and conviction of Mr. Desh Bandhu Gupta. Know more

There is only one
reason why we exist
— to treat diseases,
to heal and enrich
human life.

Dr. Desh Bandu gupta

Founder and Former Chairman, Lupin Limited

Our Values

  • Passion for Excellence

    We relentlessly pursue excellence through innovation and continuous improvement in all our projects, processes and products. We benchmark with the best in the world.

  • Entrepreneurial

    We empower our employees to generate new ideas, explore avenues and offer solutions that add exceptional value. We encourage them to build ownership in all by assuming responsibility with passion and conviction.

  • Customer Focus

    We strive to understand and meet changing customer needs in a professional and responsive manner. We focus on building long term partnerships for mutual benefit.

  • Integrity

    We conduct ourselves with uncompromising integrity and honesty with the highest standards of ethical behavior and transparency.

  • Teamwork

    We align efforts and energies of our people across all levels and geographies to deliver outstanding results for our stakeholders. We encourage diverse opinions and yet work together in a coordinated and mutually supportive way.

  • Respect and Care

    We are compassionate and sensitive towards all our stakeholders and treat them the way we would expect to be treated. We provide equal and fair opportunities for employment, learning and career development.

Our Global Footprint

Quality, Manufacturing & Compliance-

India: Aurangabad, Ankleshwar, Dabhasa, Goa, Indore, Jammu, Mandideep, Nagpur, Pune, Sikkim, Tarapur & Vizag

US: New Jersey
LATAM: Mexico & Brazil

Research

India: Pune & Aurangabad
US: New Jersey & Florida
LATAM: Mexico & Brazil
Europe: Netherlands

Marketing & Corporate Development:

More than 20 offices across the globe

Our Journey

1968

Lupin commences business

1972

Lupin Laboratories Pvt. Ltd. was incorporated

1979

Commissioned the first formulations plant and R&D Centre at Aurangabad, India

1981

Commenced the production of Ethambutol

1987

The Cephalexin plant at Mandideep and 7 ADCA plants at Ankleshwar, India, went on stream

1988

Dr. Desh Bandhu Gupta laid the foundation of the Lupin Human Welfare and Research Foundation (LHWRF). Long before CSR spend became a part of corporate lexicon, LHWRF has been working for the uplift of underprivileged communities in India through social development initiatives which are anchored by care, concern, dignity and self-respect

1989

Lupin Chemicals (Thailand) Ltd., was established through a JV in Thailand, and received U.S. FDA approvals for the Ankleshwar and Mandideep plants

1991

Production initiated of injectable Cephalosporin (bulk and dosages) at Mandideep, India

1992

Lupin Chemicals Ltd. established a sterile fermentation plant for injectable Cephalosporins (bulk) at Mandideep, India

1993

Lupin Laboratories Ltd. and Lupin Chemicals Ltd. floated IPOs

1997

Three plants — Cefaclor at Mandideep, 7 ACCA at Ankleshwar and Rifampicin at Tarapur — received U.S. FDA approvals

2000

Received U.S. FDA approval for the Cefotaxime facility at Mandideep, India

2001

Commissioned a state-of-the-art U.S. FDA-approved oral Cephalosporin bulk active plant at Mandideep, India

2001

Lupin Research Park — a state-of-the-art R&D centre —commissioned in Pune, India

2003

Received WHO approval for the state-of-the-art formulation plant, Aurangabad, India

2003

Received U.S. FDA approval for manufacturing of oral Cephalosporin at the Mandideep plant, India

2003

Lupin Pharmaceuticals Inc. USA is formed for trading, marketing and developmental activities in the U.S.

2004

Commenced the U.S. brands’ business with the launch of Suprax®

2005

Received U.S. FDA approval for new plant at Tarapur, India, to manufacture Lovastatin

2005

Received the U.S. FDA approval for Goa

2007

Acquisition of Kyowa Pharmaceutical Industry Company Ltd. (a leading generics company) in Japan

2007

Acquisition of Rubamin Laboratories Ltd., Vadodara, India (rechristened to Novodigm Ltd.)

2007

Initiation of commercial production at the dosage facility in Jammu, India

2008

Establishment of a biotech facility at Pune, India

2008

Expansion of the product portfolio in Japan-Kyowa by receiving approval for 10 products from the Ministry of Health and Labour Welfare, Japan

2008

Acquisition of Hormosan Pharma GmbH, Germany

2008

Acquisition of a stake in Generic Health Pty Ltd., Australia

2009

Acquisition of majority stake in Multi-Care Pharmaceuticals Inc., Philippines

2009

Acquisition of the U.S. rights for Antara®

2010

Lupin became the 5th largest generic player in the U.S.

2011

Initiation of commercial production at the new oral solid dosage facility at Pithampur, India

2011

Acquisition of I’rom Pharmaceuticals, Japan

2012

Lupin entered the NIFTY 50 Index

2013

Expansion of branded play by the acquisition of exclusive U.S. rights of Alinia® for oral suspensions

2014

Entered the complex injectables space with the acquisition of Nanomi B.V., Netherlands

2014

Entered the Latin American market with the acquisition of Laboratorios Grin S.A. De C.V. (a specialty ophthalmic company), Mexico

2014

Agreement for a strategic JV with Yoshindo Inc., Japan

2015

Acquisition of Pharma Dynamics, South Africa

2015

Acquisition of Medquimica Industria Farmaceutica S.A., Brazil

2015

Inauguration of the Center of Excellence for Inhalation Research, Coral Springs, Florida, U.S.

2016

Inauguration of a new plant at Visakhapatnam, India

2016

Acquisition of Gavis Pharma, New Jersey, U.S.

2016

Bolstered the brand portfolio in the U.S. with Methergine® oral tablets

2016

Commissioned a new plant at Tottori, Japan

2017

Inauguration of a new plant at Sikkim, India

2017

Entered the OTC Segment with the pan-India launch of Softovac®

2017

Acquisition of Symbiomix Therapeutics, LLC, New Jersey, U.S.

2018

Filed a new drug application in Japan for Etanercept Biosimila

2018

Commissioned A Facility For Injectables At Nagpur, India

2019

Inked pact with Boehringer Ingelheim for clinical development of MEK inhibitor for the treatment of difficult-to-treat cancers.

2019

Divestment of Kyowa Pharmaceutical Industry Co. Ltd., in Osaka

2020

Launched Etanercept Biosimilar in EU

2020

This vision drives our 1,500+ scientists and R&D personnel in 7 research centres spread across 5 countries

1968
2020

India

6th

rank in Indian
pharmaceutical market

11

brands feature in the
Top 300

India enjoys a key position in the global pharmaceutical market, supplying 20% of global generics. Lupin has built a formidable presence in India since its debut in 1968 when it started supplying Iron and Folic acid tablets to the government. Starting with Anti-TB therapy, our India business has consolidated its leadership in chronic therapies such as Cardiology, AntiDiabetes and Respiratory; while strengthening its position in the Central Nervous System (CNS), Gastrointestinal (GI) and Orthopedics space.

The India business continues to be the second largest business for Lupin, contributing 35% to our top-line, primarily driven by a strong field force of 7,000+ that reaches a majority of doctors across India. Due to the impact of COVID-19, the Indian Pharmaceutical Market (IPM) has grown at a significantly lower rate, compared to previous years. As per IQVIA, Lupin’s India business has consistently outperformed the IPM with a five- year CAGR of 10.1% as against IPM’s 8.4%. Over the last five years, Lupin’s India business has improved its market share to 3.59% in FY21. While IPM growth has shown a sharp pick-up in FY2021-22, driven by surging COVID-19-related sales, it is expected to normalize over the year as COVID-19 cases thankfully recede.

Lupin Has 11 Brands In IPM’s Top 300 Brands:

  • Gluconorm - G
  • Huminsulin
  • Budamate
  • Gibtulio
  • Cidmus
  • Ondero
  • Tonact
  • Ivabrad
  • Rablet D
  • Ajaduo
  • Ondero Met

Login or Signup

   Resend OTP

Add Address

Select your exact location

    Please select appointment date and time

      Warning

      Select appointment type